Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 369 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Polyzos, Stergios A  [Clear All Filters]
2023
Polyzos, S. A., Papaefthymiou A., Doulberis M., & Kountouras J. (2023).  Nonalcoholic fatty liver disease test: an external validation cohort.. Hormones (Athens).
Vachliotis, I. D., & Polyzos S. A. (2023).  Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease.. Curr Obes Rep.
Polyzos, S. A., Frühbeck G., & Kiortsis D. N. (2023).  Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease.. Curr Pharm Des. 29(41), 3263-3265.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Kazakos E., Tzilves D., Lazaraki G., et al. (2023).  Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B.. J Viral Hepat.
Kountouras, J., Kazakos E., Polyzos S. A., Papaefthymiou A., Zavos C., Tzitiridou-Chatzopoulou M., et al. (2023).  Potential impact of trained innate immunity on the pathophysiology of metabolic dysfunction-associated fatty liver disease.. Clin Immunol. 256, 109776.
Makras, P., Yavropoulou M. P., Polyzos S. A., Papapoulos S. E., Georgakopoulou D., Papatheodorou A., et al. (2023).  The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection.. Osteoporos Int.
Orfanidou, M., Ntenti C., Evripidou K., Mataftsi A., Goulas A., & Polyzos S. A. (2023).  Retinal Vascular Lesions in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.. J Pers Med. 13(7), 
Tsiampali, C., Papaioannidou P., Goulas A., & Polyzos S. A. (2023).  The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease.. Expert Rev Clin Pharmacol. 1-10.
Vachliotis, I. D., & Polyzos S. A. (2023).  The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease.. Curr Obes Rep.
Polyzos, S. A., Vachliotis I. D., & Mantzoros C. S. (2023).  Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease.. Metabolism. 147, 155676.
Polyzos, S. A., & Mantzoros C. S. (2023).  Sarcopenia: still in relative definition-penia and severe treatment-penia.. Metabolism. 155717.
Anastasilakis, A. D., Makras P., Paccou J., Bisbinas I., Polyzos S. A., & Papapoulos S. E. (2023).  Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab.. J Clin Med. 12(18), 
Polyzos, S. A., Goulas A., & Papaioannidou P. (2023).  Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis.. Curr Med Chem.
Vachliotis, I. D., Valsamidis I., & Polyzos S. A. (2023).  Tumor Necrosis Factor-Alpha and Adiponectin in Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma.. Cancers (Basel). 15(21), 
Polyzos, S. A., Kountouras J., Anastasilakis A. D., & Terpos E. (2023).  Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications.. Hepatobiliary Pancreat Dis Int.
2022
Anastasilakis, A. D., Polyzos S. A., Rodopaios N. E., Makras P., Kumar A., Kalra B., et al. (2022).  Activins, follistatins and inhibins in postmenopausal osteoporosis: A proof of concept, case-control study.. Metabolism. 141, 155397.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Liatsos C., Tzitiridou-Chatzopoulou M., Chatzopoulos D., et al. (2022).  Adverse Outcomes of E-cigarette in Inflammatory Bowel Disease.. Dig Dis Sci.
Polyzos, S. A., Goulis D. G., Giouleme O., Germanidis G. S., & Goulas A. (2022).  Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.. Curr Obes Rep.
Vachliotis, I. D., Vasiloglou M. F., Kapama A., Matsagkos D., Goulas A., Papaioannidou P., et al. (2022).  Association between hepatic steatosis and fibrosis indices and dietary habits, physical activity, and quality of life.. Arab J Gastroenterol.
Tontikidou, C., Makri E. S., Evripidou K., Goulis D. G., Goulas A., & Polyzos S. A. (2022).  Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: A systematic review and a meta-analysis.. J Gastroenterol Hepatol.
Makri, E. S., Makri E., & Polyzos S. A. (2022).  Combination Therapies for Nonalcoholic Fatty Liver Disease.. J Pers Med. 12(7), 
Rupp, S., Papaefthymiou A., Chatzimichael E., Polyzos S. A., Spreitzer S., Doulberis M., et al. (2022).  Diagnostic approach to -related gastric oncogenesis.. Ann Gastroenterol. 35(4), 333-344.
Anastasilakis, A. D., Papachatzopoulos S., Makras P., Gkiomisi A., Nikolakopoulos P., Polyzos S. A., et al. (2022).  The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis.. Bone. 158, 116354.
Kountouras, J., Doulberis M., Polyzos S. A., Kazakos E., Vardaka E., Tzitiridou-Chatzopoulou M., et al. (2022).  Emerging parameters relevant to the management of antimicrobial-resistant Helicobacter pylori infection.. Intern Med J. 52(9), 1654-1655.
Kountouras, J., Kazakos E., Polyzos S. A., Chatzopoulos D., Tzitiridou-Chatzopoulou M., Doulberis M., et al. (2022).  GM-CSF as a potential candidate of a vaccine-induced reduction of Helicobacter pylori infection.. Helicobacter. 27(3), e12884.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές